ATP-based tumor chemosensitivity testing: Assisting new agent development

Anti-Cancer Drugs

Volumn 10, Issue 5, 1999, Pages 431-435

  Cree, Ian A ^a   Kurbacher, Christian M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ATP; Chemosensitivity; Chemotherapy; Development; New drugs; Regimen

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; OXIPLATIN; UNCLASSIFIED DRUG; NEW DRUG;

CANCER CELL CULTURE; CHEMOSENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; PRIORITY JOURNAL; REVIEW; CANCER CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

EID: 0033462225     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199906000-00001     Document Type: Review

References (34)

1. Lane DP. The promise of molecular oncology. Lancet 1998; 351(SII): 17-20.
2. Steinberg SM, Wesley MN. Clinical trials: design and evaluation. In: Moosa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology, 2nd edn. Baltimore, MD: Williams & Wilkins 1991: 415-25.
3. Ferriman A. Patients with cancer denied best treatment. Br Med J 1998; 317: 1273.
4. Roy-Burman P, Zheng J, Miller GJ. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis? Mol Med Today 1997; 3: 476-82.
5. Tsou AP, Wu KM, Tsen TY, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998; 50: 331-40.
6. Herring CJ, West CM, Wilks DP, et al. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer 1998; 78: 1128-33.
7. Arseneau JC, Schoenfeld DA, Borden EC. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. Invest New Drugs 1986; 4: 53-6.
8. Coates AS, Bishop J, Mann GJ, Raghavan D. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. Eur J Cancer Clin Oncol 1986; 22: 97-100.
9. Grover R, Chana JS, Wilson GD, Richman PI, Sanders R. An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res 1998; 8: 267-72.
10. Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case control study. Int J Cancer 1998; 77: 843-8.
11. Fuchs B, Ostmeier H, Suter L. P-glycoprotein expression in malignant melanoma. J Cancer Res Clin Oncol 1991: 117: 168-71.
12. Cowan JD, Nekthart J, McClure S, et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 1077-84.
13. Dieras V, Marty M, Tubiana N, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995; 22 (suppl 8): 33-9.
14. Kurbacher CM, Cree IA, Brenne LT, et al. Heterogencity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by microplate ATP bioluminescence assay. Breast Cancer Res Treat 1996; 41: 161-70.
15. Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3: 1527-33.
16. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro essays. Drugs 1992; 44: 690-708.
17. Bosanquet AG. In vitro drug sensitivity testing for the individual patient: an ideal adjunct to current methods of treatment choice. Clin Oncol 1993; 5: 195-7.
18. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumours - is there any alternative? Anti-Cancer Drugs 1997; 8: 541-8.
19. Steel M. Polymorphisms, proteins, and phenotypes. Lancet 1993; 341: 212-3.
20. Kurbacher CM, Cree IA, Bruckner HW, Mallmann P, Andreotti PE. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs 1998; 9: 51-7.
21. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
22. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 1996; 7: 630-5.
23. Kurbacher CM, Untch M, Cree LA. A randomised trial of chemotherapy directed by a tumour chemosensitivity assay versus physician's choice in patients with recurrent platinum-resistant ovarian adenocarcinoma. Lancet Internet publication 1997a: http://www.thelancet.com/newlancet/sub/author//menu_NOD7.html
24. Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. Anti-Cancer Drugs 1997; 8: 756-62.
25. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for chroroidal melanoma: ex vivo sensitivity to treosulfaln with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79: 1487-93.
26. Kurbacher CM, Mallmann P, Kurbacher JA, et al. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer. Anticancer Res 1994; 14: 1961-5.
27. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biophys Biochem Res Commun 1994; 199: 264-70.
28. Cree IA, Petty RD, Sutherland LA, et al. Elucidation of molecular determinants of tumour chemosensitivity by ATP-based luminescence assay. In: Campbell AC, Stanley PE, Kricka LJ, eds. Chemluminescence and bioluminescence. Chichester: John Wiley 1994; 407-10.
29. Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992; 19: 622-38
30. Budman DR, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-Cancer Drugs 1998; 9: 697-702.
31. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumor chemosensitivity, assay: differences in sensitivity between cultured tumor cell lines and clinical studies. J Biolumin Chemilumin 1994; 9: 373-8.
32. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs - 21st Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4: 1079-86.
33. Hanauskc AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
34. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxiplatin against human tumor colonyforming units. Clin Cancer Res 1998; 4: 1021-9.